Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma.
BRAF inhibition therapy, used to treat melanomas with BRAF mutations, is associated with both neoplastic and non-neoplastic cutaneous side effects including squamous cell carcinomas, warty dyskeratomas, verrucous keratoses, photosensitivity and widespread eruptions that present histopathologically as acantholytic dyskeratosis. We report a case of a patient undergoing BRAF inhibition therapy for disseminated melanoma with a V600E mutation who developed bilateral areolar leiomyomas, one of which was biopsied and the other of which resolved after discontinuation of vemurafenib therapy. To our knowledge, this is the first reported case of a mesenchymal neoplasm developing in association with BRAF inhibition therapy.
Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA,; University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
Michael
M
Clarke
Bernhard
B
Ortel
Bruce
B
Brockstein
Theera
T
Rojanapremsuk
Thomas
T
Victor
Antoinette
A
Thomas
Thomas
T
Cibull
D000368:Aged; D019943:Amino Acid Substitution; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D007889:Leiomyoma / Q000139:chemically induced* / Q000201:enzymology / Q000473:pathology*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D020125:Mutation, Missense; D016609:Neoplasms, Second Primary / Q000201:enzymology / Q000473:pathology*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D000077484:Vemurafenib
D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
Braf; cutaneous neoplasm; leiomyoma; malignant melanoma